肝硬化并发菌血症研究进展

王静云; 孙晶; 高沿航

doi:10.3969/j.issn.1001-5256.2014.07.030

肝硬化并发菌血症研究进展

DOI: 10.3969/j.issn.1001-5256.2014.07.030

吉林大学第一医院肝胆胰内科

基金项目:

国家自然科学基金(81001312)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2408
- HTML全文浏览量: 6
- PDF下载量: 697
- 被引次数: 0
出版历程
- 收稿日期: 2013-09-02
- 出版日期: 2014-07-20

Research advances in liver cirrhosis complicated by bacteremia

Department of Hepatic Biliary Pancreatic Medicine, First Hospital, Jilin University

Research funding:

摘要

摘要: 菌血症是肝硬化患者的常见并发症,肝硬化菌血症的发生率随肝病严重程度递增,一旦发生菌血症,则提示预后较差。叙述了肝硬化并发菌血症的危险因素、诊断要点、治疗方法、预防及预后五个方面的研究进展,认为早期防治菌血症对肝硬化患者的预后有重要意义。
- 肝硬化 /
- 菌血病 /
- 综述
Abstract: Bacteremia is a common complication in patients with liver cirrhosis, and its incidence rises as the severity of liver disease increases. Liver cirrhosis complicated by bacteremia will lead to poor prognosis. The research progress in liver cirrhosis complicated by bacteremia is reviewed from the following aspects: risk factors, diagnostic points, treatment methods, prevention, and prognosis. It is believed that early prevention and treatment of bacteremia have great significance for the prognosis of patients with liver cirrhosis.
- liver cirrhosis /
- bacteremia /
- review

HTML全文

参考文献(25)

[1]FERNNDEZ J, NAVASA M, GMEZ J, et al.Bacterial infections in cirrhosis:epidemiological changes with invasive procedures and norfloxacin prophylaxis[J].Hepatology, 2002, 35 (1) :140-148.

[2]BUNCHORNTAVAKUL C, CHAVALITDHAMRONG D.Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis[J].World J Hepatol, 2012, 4 (5) :158-168.

[3]GHASSEMI S, GARCIA-TSAO G.Prevention and treatment of infections in patients with cirrhosis[J].Best Pract Res Clin Gastroenterol, 2007, 21 (1) :77-93.

[4]BELLOT P, FRANCS R, SUCH J.Pathological bacterial translocation in cirrhosis:pathophysiology, diagnosis and clinical implications[J].Liver Int, 2013, 33 (1) :31-39.

[5] HASHIMOTO N, OHYANAGI H.Effect of acute portal hypertension on gut mucosa[J].Hepatogastroenterology, 2002, 49 (48) :1567-1570.

[6]YIN XJ.Risk factors for liver cirrhosis combined with nosocomial infections[J].Chin J Nosocomiol, 2012, 22 (8) :1624-1625. (in Chinese) 殷晓俊.肝硬化合并医院感染的危险因素分析[J].中华医院感染学杂志, 2012, 22 (8) :1624-1625.

[7]HARTMANN P, CHEN WC, SCHNABL B.The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease[J].Front Physiol, 2012, 3:402.

[8]PAPP M, VITALIS Z, ALTORJAY I, et al.Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections[J].Liver Int, 2012, 32 (4) :603-611.

[9]LI CH, YANG RB, PANG JH, et al.Procalcitonin as a biomarker for bacterial infections in patients with liver cirrhosis in the emergency department[J].Acad Emerg Med, 2011, 18 (2) :121-126.

[10]JEONG S, PARK Y, CHO Y, et al.Diagnostic utilities of procalcitonin and C-reactive protein for the prediction of bacteremia determined by blood culture[J].Clin Chim Acta, 2012, 413 (21-22) :1731-1736.

[11]YILMAZ G, MENTESE A, KAYA S, et al.The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever[J].J Clin Virol, 2011, 50 (3) :209-211.

[12]HUTTUNEN R, SYRJNEN J, VUENTO R, et al.Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia:a prospective cohort study[J].J Intern Med, 2011, 270 (1) :32-40.

[13]GAO K, ZHANG LF.Progress in interleukin and tumors[J].Chin J Immunol, 2012, 28 (5) :467-470. (in Chinese) 高昆, 张连峰.白细胞介素与肿瘤研究进展[J].中国免疫学杂志, 2012, 28 (5) :467-470.

[14]HOENIGL M, RAGGAM RB, WAGNER J, et al.Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome[J].Clin Biochem, 2013, 46 (3) :225-229.

[15]GUSTOT T, DURAND F, LEBREC D, et al.Severe sepsis in cirrhosis[J].Hepatology, 2009, 50 (6) :2022-2033.

[16]GUO TS, QU F, MAO YL, et al.Research on the distribution and antibiotics resistance sepectrum of bacteria isolated from blood cultures in patients with chronic hepatopathy[J].J Int Inten Med, 2006, 12 (3) :105-107. (in Chinese) 郭桐生, 曲芬, 毛远丽, 等.慢性肝病患者血培养分离菌分布特征及耐药谱研究[J].内科急危重症杂志, 2006, 12 (3) :105-107.

[17]SHIZUMA T, FUKUYAMA N.Investigation into bacteremia and spontaneous bacterial peritonitis in patients with liver cirrhosis in Japan[J].Turk J Gastroenterol, 2012, 23 (2) :122-126.

[18] PATERSON DL, BONOMO RA.Extended-spectrum beta-lactamases:a clinical update[J].Clin Microbiol Rev, 2005, 18 (4) :657-686.

[19]SKOV R, CHRISTIANSEN K, DANCER SJ, et al.Update on the prevention and control of community-acquired meticillin-resistant Staphylococcus aureus (CA-MRSA) [J].Int J Antimicrob A-gents, 2012, 39 (3) :193-200.

[20]FELDMAN C, ANDERSON R.Bacteraemic pneumococcal pneumonia:current therapeutic options[J].Drugs, 2011, 71 (2) :131-153.

[21]ARIAS CA, MENDES RE, STILWELL MG, et al.Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections[J].Clin Infect Dis, 2012, 54 (Suppl 3) :s233-s238.

[22]ANTHONY KB, FISHMAN NO, LINKIN DR, et al.Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline[J].Clin Infect Dis, 2008, 46 (4) :567-570.

[23]VILA J, MARCO F, SOLER L, et al.In vitro antimicrobial susceptibility of clinical isolates of Aeromonas caviae, Aeromonas hydrophila and Aeromonas veronii biotype sobria[J].J Antimicrob Chemother, 2002, 49 (4) :701-702.

[24]ARVANITI V, D'AMICO G, FEDE G, et al.Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J].Gastroenterology, 2010, 139 (4) :1246-1256.e1-5.

[25]WU HQ, WANG H.Diagnosis and treatment of spontaneous bacterial peritonitis in patients with liver ascite[J].J Clin Hepatol, 2012, 28 (9) :651-653. (in Chinese) 吴海清, 王晖.肝硬化腹水伴自发性细菌性腹膜炎的诊断及治疗[J].临床肝胆病杂志, 2012, 28 (9) :651-653.

施引文献

资源附件(0)

访问统计